[Federal Register Volume 68, Number 109 (Friday, June 6, 2003)]
[Notices]
[Page 33960]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-14263]



[[Page 33960]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should inform the contact person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee (RAC).
    Date: June 18, 2003.
    Open: 8:30 a.m. to 5 p.m.
    Agenda: In addition to protocol review and Data Management, the 
NIH RAC will: Review presentations from the 2003 annual meeting of 
the American Society of Gene Therapy relevant to retroviral vectors; 
discuss the Recommendations of the United Kingdom Gene Therapy 
Advisory Committee and Committee of Safety of Medicine on 
Retroviruses; discuss future presentations to the RAC on retroviral 
gene transfer; and discuss an in-depth assessment regarding 
containment level requirements for Modified Vaccinia Ankara Pox 
viral vectors.
    Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, 
MD 20814.

    Name of Committee: Recombinant DNA Advisory Committee (RAC).
    Date: June 19, 2003.
    Open: 8:30 a.m. to 12 p.m.
    Agenda: A presentation on preliminary results of an NIH-funded 
research project on informed consent and review and discuss the RAC 
Informed Consent Working Group draft guidance document.
    Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, 
MD 20814.
    Contact: Stephen Rose, PhD, Executive Secretary, Recombinant DNA 
Advisory Committee, Office of Biotechnology Activities, Rockledge 1, 
Room 750, Bethesda, MD 20892, (301) 396-9839.
    Information is also available on the Institute's/Center's Home 
page: www4.od.nih.gov/oba, where an agenda and any additional 
information for the meeting will be posted when available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecules techniques could 
be used, it has been determined not to be cost effective or in the 
pubic interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual programs listed in the Catalog of Federal 
Domestic Assistance are affected

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.187, Undergraduate 
Scholarship Program for Individuals from Disadvantaged Backgrounds; 
93.22, Clinical Research Loan Repayment Program for Individuals from 
Disadvantaged Backgrounds; 93.232, Loan Repayment Program for 
Research Generally; 93.39, Academic Research Enhancement Award; 
93.936, NIH Acquired Immunodeficiency Syndrome Research Loan 
Repayment Program, National Institutes of Health, HHS)

    Dated: May 29, 2003.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 03-14263 Filed 6-5-03; 8:45 am]
BILLING CODE 4140-01-M